Cargando…
Evaluation of prostate cancer prevalence in Iranian male population with increased PSA level, a one center experience
PURPOSE: This study was conducted to evaluate the incidence of prostate cancer (PCa) in Iranian male patients with increased prostate-specific antigen (PSA), and normal or abnormal digital rectal examination (DRE) that underwent prostate biopsy. MATERIALS AND METHODS: From March 2006 to April 2009,...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3139483/ https://www.ncbi.nlm.nih.gov/pubmed/21792331 http://dx.doi.org/10.2147/CMR.S18147 |
_version_ | 1782208464913694720 |
---|---|
author | Moslemi, Mohammad Kazem Lotfi, Fariborz Tahvildar, Seyed Ali |
author_facet | Moslemi, Mohammad Kazem Lotfi, Fariborz Tahvildar, Seyed Ali |
author_sort | Moslemi, Mohammad Kazem |
collection | PubMed |
description | PURPOSE: This study was conducted to evaluate the incidence of prostate cancer (PCa) in Iranian male patients with increased prostate-specific antigen (PSA), and normal or abnormal digital rectal examination (DRE) that underwent prostate biopsy. MATERIALS AND METHODS: From March 2006 to April 2009, a total of 346 consecutive males suspected of having PCa due to increased PSA levels underwent transrectal ultrasonography (TRUS)-guided sextant biopsy of the prostate. The total PSA (tPSA), demographic data, incidence of PCa, benign prostate hyperplasia (BPH), and prostatitis were assessed. RESULTS: The patients were divided into two groups according to their PSA values (group A serum tPSA level, 4–10 ng/mL; group B serum tPSA level, 10.1–20.0 ng/mL). Of the 346 biopsied cases, 193 cases (56%) had PCa, 80 cases (23%) had BPH, and 73 cases (21%) had prostatitis. The mean PSA and the age of the carcinoma group were significantly higher than those of the benign group (P < 0.01). The biopsy results were grouped as PCa, BPH, and prostatitis. Incidence of PCa for group A and group B cases were 115 cases (51%), and 78 cases (65%), respectively. In the case of PCa, BPH, and prostatitis, the mean PSAs were 10.02 ng/mL, 8.76 ng/mL, and 8.41 ng/mL, respectively (P < 0.40). CONCLUSION: TRUS-guided prostate biopsy and interpretation by a skilled team is highly recommended for early detection of PCa or its ruling-out. It seems that a PSA cutoff value of 4 ng/mL may be applied to the Iranian population. Although the chance of PCa is high in the PSA levels of 4–10 ng/mL, the combination of some data, like age and prostate volume, can decrease the rate of unnecessary prostate biopsies. We recommend prostate biopsy when PSA and/or DRE is elevated in symptomatic patients with obstructive and/or irritative lower urinary tract symptoms (LUTS) such as dysuria, frequency, or nocturia. Due to the very high incidence of PCa in the patients with PSA greater than 10 ng/mL, TRUS-guided biopsy is indicated, whatever the findings on DRE and/or LUTS, since the PCa detection rate is high. |
format | Online Article Text |
id | pubmed-3139483 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-31394832011-07-26 Evaluation of prostate cancer prevalence in Iranian male population with increased PSA level, a one center experience Moslemi, Mohammad Kazem Lotfi, Fariborz Tahvildar, Seyed Ali Cancer Manag Res Original Research PURPOSE: This study was conducted to evaluate the incidence of prostate cancer (PCa) in Iranian male patients with increased prostate-specific antigen (PSA), and normal or abnormal digital rectal examination (DRE) that underwent prostate biopsy. MATERIALS AND METHODS: From March 2006 to April 2009, a total of 346 consecutive males suspected of having PCa due to increased PSA levels underwent transrectal ultrasonography (TRUS)-guided sextant biopsy of the prostate. The total PSA (tPSA), demographic data, incidence of PCa, benign prostate hyperplasia (BPH), and prostatitis were assessed. RESULTS: The patients were divided into two groups according to their PSA values (group A serum tPSA level, 4–10 ng/mL; group B serum tPSA level, 10.1–20.0 ng/mL). Of the 346 biopsied cases, 193 cases (56%) had PCa, 80 cases (23%) had BPH, and 73 cases (21%) had prostatitis. The mean PSA and the age of the carcinoma group were significantly higher than those of the benign group (P < 0.01). The biopsy results were grouped as PCa, BPH, and prostatitis. Incidence of PCa for group A and group B cases were 115 cases (51%), and 78 cases (65%), respectively. In the case of PCa, BPH, and prostatitis, the mean PSAs were 10.02 ng/mL, 8.76 ng/mL, and 8.41 ng/mL, respectively (P < 0.40). CONCLUSION: TRUS-guided prostate biopsy and interpretation by a skilled team is highly recommended for early detection of PCa or its ruling-out. It seems that a PSA cutoff value of 4 ng/mL may be applied to the Iranian population. Although the chance of PCa is high in the PSA levels of 4–10 ng/mL, the combination of some data, like age and prostate volume, can decrease the rate of unnecessary prostate biopsies. We recommend prostate biopsy when PSA and/or DRE is elevated in symptomatic patients with obstructive and/or irritative lower urinary tract symptoms (LUTS) such as dysuria, frequency, or nocturia. Due to the very high incidence of PCa in the patients with PSA greater than 10 ng/mL, TRUS-guided biopsy is indicated, whatever the findings on DRE and/or LUTS, since the PCa detection rate is high. Dove Medical Press 2011-06-27 /pmc/articles/PMC3139483/ /pubmed/21792331 http://dx.doi.org/10.2147/CMR.S18147 Text en © 2011 Moslemi et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Original Research Moslemi, Mohammad Kazem Lotfi, Fariborz Tahvildar, Seyed Ali Evaluation of prostate cancer prevalence in Iranian male population with increased PSA level, a one center experience |
title | Evaluation of prostate cancer prevalence in Iranian male population with increased PSA level, a one center experience |
title_full | Evaluation of prostate cancer prevalence in Iranian male population with increased PSA level, a one center experience |
title_fullStr | Evaluation of prostate cancer prevalence in Iranian male population with increased PSA level, a one center experience |
title_full_unstemmed | Evaluation of prostate cancer prevalence in Iranian male population with increased PSA level, a one center experience |
title_short | Evaluation of prostate cancer prevalence in Iranian male population with increased PSA level, a one center experience |
title_sort | evaluation of prostate cancer prevalence in iranian male population with increased psa level, a one center experience |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3139483/ https://www.ncbi.nlm.nih.gov/pubmed/21792331 http://dx.doi.org/10.2147/CMR.S18147 |
work_keys_str_mv | AT moslemimohammadkazem evaluationofprostatecancerprevalenceiniranianmalepopulationwithincreasedpsalevelaonecenterexperience AT lotfifariborz evaluationofprostatecancerprevalenceiniranianmalepopulationwithincreasedpsalevelaonecenterexperience AT tahvildarseyedali evaluationofprostatecancerprevalenceiniranianmalepopulationwithincreasedpsalevelaonecenterexperience |